<<

    About Helix BioPharma Corp.
    >>

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF."

    <<

    About Merriman Curhan Ford
    >>

Merriman Curhan Ford (Nasdaq: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural Resources and Technology. For more information, please go to www.mcfco.com.

    <<
    For further information contact:
    Investor Relations
    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel: (212) 845-4226
    Email:  robert.flamm@russopartnersllc.com
    www.russopartnersllc.com
    >>

    <<
    Media Relations
    Ian Stone
    Russo Partners LLC
    Tel: (619) 814-3510
    Fax: (619) 955-5318
    Email: ian.stone@russopartnersllc.com


    >>

This News Release contains certain forward-looking statements and information (collectively, "forward-looking statements") regarding the Company's planned presentation at Merriman Curhan Ford's 6th annual Investor Summit and the Company's research and development initiatives, which statements can be identified by the use of forward looking terminology such as "will", "developing", "November 10, 2009", or comparable forward-looking terminology. Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the fact that the presentation and the posting of the slide show portion of the presentation on the Company's website are subject to change or cancellation without notice; Helix's need for additional future capital, which may not be available in a timely manner or at all; the need for additional research and development, the outcome of which is uncertain; and uncertainty whether L-DOS47 or Topical Interferon Alpha-2b, or any other product development initiatives, will be successfully developed or commercialized. See the Company's latest Form 20-F and other reports filed from time to time on SEDAR at www.sedar.com, and on EDGAR at www.sec.gov/edgar.shtml for a further description of certain of these and other important risks and uncertainties affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements. The Company does not assume any obligation to update any forward-looking statement except as required by law. The Company has relied solely on Merriman Curhan Ford for the information about them provided in this News Release and the Company disclaims any liability with respect to such information or with respect to information contained in their website, which is referenced for convenience only and not as an endorsement by Helix of such website.

    <<



    >>

SOURCE: Helix BioPharma Corp.

Investor Relations, Robert Flamm, Ph.D., +1-212-845-4226,
robert.flamm@russopartnersllc.com; or Media Relations, Ian Stone, +1-619-814-3510 or
Fax, +1-619-955-5318, ian.stone@russopartnersllc.com, both of Russo Partners LLC Web
Site: http://www.helixbiopharma.com

In October 2009, Ford brand sales increased 3.6% to 119,072 units, compared to 114,969 units in October 2008. Volvo brand sales increased 19.4% to 4,437 units in October 2009 from 3,717 units in October 2008.

Sales of Lincoln brand vehicles decreased 9% to 6,735 units, compared to 7,399 units in October 2008, while Mercury brand sales decreased 1.1% to 6,676 units, compared to 6,753 units in October 2008.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

CONTACT:

    VIVUS, Inc.                 Investor Relations:  The Trout Group
    Timothy E. Morris                                Brian Korb
    Chief Financial Officer                          646-378-2923
    650-934-5200
                                Media Relations:     Pure Communications, Inc.
                                                     Dan Budwick
                                                     973-271-6085

SOURCE VIVUS, Inc.

http://www.vivus.com

About Celldex Therapeutics, Inc.

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.

About Merriman Curhan Ford

Merriman Curhan Ford (NASDAQ: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural Resources and Technology. For more information, please go to www.mcfco.com.

SOURCE: Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. 
Anthony S. Marucci, 781-433-0771 
President and CEO 
or 
Avery W. Catlin, 781-433-0771 
Chief Financial Officer 
IR@celldextherapeutics.com 
or 
Celldex Investor Relations: 
MacDougall Biomedical Communications 
Sarah Cavanaugh, 781-235-3060 
scavanaugh@macbiocom.com 
or 
Celldex Media: 
BMC Communications Group 
Matthew Driscoll, 212-477-9007 x20 
mdriscoll@bmccommunications.com